![Drug manufacturing laboratory equipment](https://www.nortonrosefulbright.com/-/media/images/nrf/thought-leadership/canada/publications/life-sciences-healthcare-lab-equipment.jpg?w=265&revision=355955d3-b814-40be-80c7-63b3ad62cb43&revision=5248910870347387904&hash=1F3BEDB56F2489EB29C4E2FCBDED3656)
Publication
Health Canada identifies lithium-ion batteries, infant bath seats, and water beads as hazards of concern
Health Canada has recently identified three new classes of products that pose a hazard of concern.
Global | Publication | January 2019
The convergence of technology and life sciences was a defining feature of 2018. The boundaries of what defines the life sciences sector have increasingly blurred as life sciences companies look to the value of data in the search for innovation.
This does not mean, however, that “traditional” life sciences transactions are not going ahead. Some of the largest global deals have involved the acquisition of “traditional” research and development assets.
Case study
Norton Rose Fulbright advised on the sale of Acumyn Inc., a healthcare technology company, to a global Swedish health technology company, Elekta. This included negotiating Acumyn’s joint development and marketing agreement with Elekta, as well as acting on a number of complex mandates related to Acumyn’s technology and licensing with University Health Network, a leading Toronto based hospital network.
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Publication
Health Canada has recently identified three new classes of products that pose a hazard of concern.
Publication
An employer’s ability to ask for a sick note when an employee is absent from work due to illness is becoming increasingly curtailed across Canada.
Publication
Since 2022, the Government of Canada has introduced three waves of amendments to the Competition Act (Act), making substantive changes to Canada’s competition laws, with the most recent amendments receiving royal assent on June 20, 2024.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023